The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential

References

• Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe biomed study group. Annals of Oncology. 1997;8(Suppl 2):S49–54.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20;346(25):1937–1947.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003 Sep 15;198(6):851–862.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Jardin F, Pujals A, Pelletier L, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am J Hematol. 2016 Sep;91(9):923–930.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003 Dec 1;102(12):3871–3879.
   PubMed Web of Science ®Google Scholar
• Choi WWL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009 Sep 1;15(17):5494–5502.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 Jan 1;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012 Sep;26(9):2103–2113.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 May;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol Off J Am Soc Clin Oncol. 2005 Jun 20;23(18):4117–4126.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes Da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2015 Sep;26(Suppl 5):v116–125.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, van den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010 Sep 23;116(12):2040–2045.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. 2006 Jul 1;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014 Jan;11(1):12–23.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Coiffier B. Primary refractory diffuse large B cell lymphoma in the rituximab era. Curr Opin Oncol. 2015 Sep;27(5):377–383.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet Lond Engl. 2013 May 25;381(9880):1817–1826.
   PubMed Web of Science ®Google Scholar
• Camus V, Tilly H. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma. Expert Rev Hematol. 2016 Nov;16:1–9.
   Google Scholar
• Duehrsen U, Hüttmann A, Müller S, et al. Positron Emission Tomography (PET) Guided therapy of aggressive lymphomas – a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). Blood. 2014 Dec 6;124(21):391–391.
   Web of Science ®Google Scholar
• Sehn LH, Hardy ELG, Gill KK, et al. Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood. 2014 Dec 6;124(21):392–392.
   Google Scholar
• Casasnovas R-O, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011 Jul 7;118(1):37–43.
   PubMed Web of Science ®Google Scholar
• Gouill SL, Milpied NJ, Lamy T, et al. First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol. [Internet]. 2011;29:suppl; abstr 8003. [cited 2017 Feb 2]. Available from: http://meetinglibrary.asco.org/content/84038-102
   Google Scholar
• Weeks JC, Yeap BY, Canellos GP, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol Off J Am Soc Clin Oncol. 1991 Jul;9(7):1196–1203.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Vose JM. To surveil or not to surveil. J Clin Oncol. 2015 Dec 1;33(34):3983–3984.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Computed tomography — an increasing source of radiation exposure. N Engl J Med. 2007 Nov 29;357(22):2277–2284.
   PubMed Web of Science ®Google Scholar
• Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol Off J Am Soc Clin Oncol. 2015 May 1;33(13):1467–1474.
   PubMed Web of Science ®Google Scholar
• Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014 Nov 1;32(31):3506–3512.
   PubMed Web of Science ®Google Scholar
• Am L, Ansell SM, P A, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase ib study. J Clin Oncol Off J Am Soc Clin Oncol. 2016 Aug 10;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015 Aug;21(8):846–853.
   PubMed Web of Science ®Google Scholar
• Antón Aparicio LM, Medina V, Valladares Ayerbes M, et al. Circulating microRNAs as potential biomarkers in patients with renal tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Feb 10;30(5_suppl):405.
   Web of Science ®Google Scholar
• Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol Off J Am Soc Clin Oncol. 2014 Feb 20;32(6):579–586.
   PubMed Web of Science ®Google Scholar
• Lowes LE, Bratman SV, Dittamore R, et al. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation. Int J Mol Sci. 2016 Sep 8;17:9.
   Web of Science ®Google Scholar
• Shaw JA, Guttery DS, Hills A, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts. Clin Cancer Res. 2017;23(1):88–96.
   Google Scholar
• Bohers E, Viailly PJ, Dubois S, et al. Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica. 2015 Jul;100(7):e280–284.
   PubMed Web of Science ®Google Scholar
• Mancuso P, Calleri A, Antoniotti P, et al. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer. 2010 Nov 24;10:644.
   PubMed Web of Science ®Google Scholar
• Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016 Jul 14;128(2):185–194.
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Carneiro BA, et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016;7(40):65364–65373.
   Google Scholar
• Huang A, Zhang X, Zhou S-L, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer. 2016;7(13):1907–1914.
   PubMed Web of Science ®Google Scholar
• Liao W, Yang H, Xu H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget. 2016 Jun 28;7(26):40481–40490.
   PubMed Web of Science ®Google Scholar
• Armand P, Oki Y, Neuberg DS, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct;163(1):123–126.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015 Jun 11;125(24):3679–3687.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015 May;16(5):541–549.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Redmond D, Nie K, et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol. 2014 Aug 15;15(8):432.
   PubMed Web of Science ®Google Scholar
• Rizzo D, Viailly P-J, Mareschal S, et al. Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas. Am J Hematol. 2016;92(1):68–76.
   Google Scholar
• Leithäuser F, Bäuerle M, Huynh MQ, et al. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood. 2001 Nov 1;98(9):2762–2770.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Nie K, Redmond D, et al. Elemento O. VDJ-Seq: deep sequencing analysis of rearranged immunoglobulin heavy chain gene to reveal clonal evolution patterns of B cell lymphoma. J Vis Exp Jove. 2015 Dec;28(106):e53215.
   Google Scholar
• Morin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 May 1;22(9):2290–2300.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009 Jun 4;459(7247):717–721.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan 7;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Bohers E, Mareschal S, Bouzelfen A, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2014 Feb;53(2):144–153.
   PubMed Web of Science ®Google Scholar
• Dubois S, Mareschal S, Picquenot J-M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015 Jun 30;6(18):16712–16724.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Dubois S, Viailly P-J, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2016 Mar;55(3):251–267.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly P-J, Mareschal S, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 Jun 15;22(12):2919–2928.
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Rj L, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• Goh H-G, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011 May;52(5):896–904.
   PubMed Web of Science ®Google Scholar
• Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013 Oct;10(10):1003–1005.
   PubMed Web of Science ®Google Scholar
• Pereira E, Camacho-Vanegas O, Anand S, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. Plos One. 2015 déc;10(12):e0145754.
   PubMed Web of Science ®Google Scholar
• Dubois S, Mareschal S, Picquenot J-M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015;6(18):16712–16724.
   Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Oct 10;492(7427):108–112.
   PubMed Web of Science ®Google Scholar
• Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014 Apr;13(4):842–854.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011 Feb 3;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly P-J, Bohers E, et al. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P mutated diffuse large B-cell lymphoma: analysis of 361 cases. Clin Cancer Res. 2016. doi:10.1158/1078-0432.CCR-16-1922. [Epub ahead of print].
   Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. [Internet]. 2015 Jul 20 [cited 2015 Jul 21]; Available from: http://www.nature.com/doifinder/10.1038/nm.3884
   Web of Science ®Google Scholar
• Alcaide M, Yu S, Bushell K, et al. Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin Chem. 2016 Sep;62(9):1238–1247.
   PubMed Web of Science ®Google Scholar
• Dugo N, Padula F, Mobili L, et al. Six consecutive false positive cases from cell-free fetal DNA testing in a single referring centre. J Prenat Med. 2014;8(1–2):31–35.
   PubMedGoogle Scholar
• Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med. [Internet]. 2014 Nov [cited 2016 Dec 16]; 2: 11. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245510/
   Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548–554.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016 Nov 9;8(364):364ra155.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM. Development and validation of biopsy-free genotyping for molecular subtyping of diffuse large B-cell lymphoma. In Abstract 1089 ASH 2016; 2016 [cited 2016 Dec 31]; Available from: https://ash.confex.com/ash/2016/webprogram/Paper95362.html
   Google Scholar
• Bratman SV, Newman AM, Alizadeh AA, et al. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn. 2015 Jun 3;15(6):715–719.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Scherer F, Newman AM, et al. Dynamic noninvasive genomic monitoring for outcome prediction in diffuse large B-cell lymphoma. Blood. 2015 Dec 3;126(23):130–130.
   PubMed Web of Science ®Google Scholar
• Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947–1957.
   Google Scholar
• Elshimali Y, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013 Sep 13;14(9):18925–18958.
   PubMed Web of Science ®Google Scholar
• Adams HJA, Jmh DK, Fijnheer R, et al. Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: does it have any prognostic value? J Comput Assist Tomogr. 2015 Oct;39(5):810–815.
   PubMed Web of Science ®Google Scholar
• Dabaja BS, Phan J, Mawlawi O, et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec;54(12):2631–2638.
   PubMed Web of Science ®Google Scholar
• Rusak M, Ł B, Chociej-Stypułkowska J, et al. Flow-cytometry-based evaluation of peripheral blood lymphocytes in prognostication of newly diagnosed DLBCL patients. Blood Cells Mol Dis. 2016 Jul;59:92–96.
   PubMed Web of Science ®Google Scholar
• Sugita Y, Ohwada C, Kawaguchi T, et al. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospective analysis. Clin Chim Acta Int J Clin Chem. 2016 Oct 8;463:47–52.
   PubMed Web of Science ®Google Scholar
• Wu J-Z, Tian T, Huang Y, et al. Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma. Cancer Biomark Sect Dis Markers. 2016 Jul 8;17(2):205–212.
   PubMed Web of Science ®Google Scholar
• Sun H-L, Pan Y-Q, He B-S, et al. Prognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: an updated meta-analysis of eleven reports. Oncotargets Ther. 2016;9:3017.
   PubMed Web of Science ®Google Scholar
• Xia W-K, Lin Q-F, Shen D, et al. Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis. FEBS Open Bio. 2016 Jun;6(6):558–565.
   PubMed Web of Science ®Google Scholar
• Tamaddon G, Geramizadeh B, Karimi MH, et al. miR-4284 and miR-4484 as putative biomarkers for diffuse large B-cell lymphoma. Iran J Med Sci. 2016 Jul;41(4):334–339.
   PubMed Web of Science ®Google Scholar
• Yuan WX, Gui YX, Na WN, et al. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett. 2016 Jan;11(1):423–432.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Li X, Zhu Y, et al. Prognostic significance of miRNA in patients with diffuse large B-cell lymphoma: a meta-analysis. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2016;39(5):1891–1904.
   PubMed Web of Science ®Google Scholar
• Melani C, Roschewski M. Molecular monitoring of cell-free circulating tumor DNA in non-hodgkin lymphoma. Oncol Williston Park N. 2016 Aug;30:8.
   PubMed Web of Science ®Google Scholar
• Yamada S, Ishida Y, Matsuno A, et al. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015 Jul;56(7):2141–2145.
   PubMed Web of Science ®Google Scholar
• Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016 Sep;57(9):2171–2179.
   PubMed Web of Science ®Google Scholar
• Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2017;129(3):280–288.
   Google Scholar
• Cottereau A-S, Lanic H, Mareschal S, et al. Molecular profile and FDG-PET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 Aug 1;22(15):3801–3809.
   PubMed Web of Science ®Google Scholar